Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 16;8(1):15.
doi: 10.3390/brainsci8010015.

Glioblastoma under Siege: An Overview of Current Therapeutic Strategies

Mayra Paolillo  1 , Cinzia Boselli  2 , Sergio Schinelli  3
Affiliations
Review

Glioblastoma under Siege: An Overview of Current Therapeutic Strategies

Mayra Paolillo et al. Brain Sci. .

Abstract

Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to be targeted by a variety of therapeutic approaches, including novel pharmaceutical formulations and immunotherapy strategies. In this review, we will first discuss current molecular classification based on genomic and transcriptomic criteria. Also, the state of the art in current clinical practice for glioblastoma therapy in the light of the recent molecular classification, together with ongoing phases II and III clinical trials, will be described. Finally, new pharmaceutical formulations such as nanoparticles and viral vectors, together with new strategies entailing the use of monoclonal antibodies, vaccines and immunotherapy agents, such as checkpoint inhibitors, will also be discussed.

Keywords: alkylating agents; immunotherapy; monoclonal antibodies; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Di Carlo D.T., Cagnazzo F., Benedetto N., Morganti R., Perrini P. Multiple high-grade gliomas: Epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg. Rev. 2017:1–13. doi: 10.1007/s10143-017-0928-7. - DOI - PubMed
    1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. WHO Classification of Tumours of the Central Nervous System. Revised 4th ed. International Agency for Research on Cancer (IARC); Lyon, France: 2016. pp. 10–122.
    1. Verhaak R.G.W., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020. - DOI - PMC - PubMed
    1. Reifenberger G., Wirsching H.G., Knobbe-Thomsen C.B., Weller M. Advances in the molecular genetics of gliomas—Implications for classification and therapy. Nat. Rev. Clin. Oncol. 2017;14:434–452. doi: 10.1038/nrclinonc.2016.204. - DOI - PubMed
    1. Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: Merging genomic and histopathological classification for personalised therapy. Br. J. Cancer. 2011;104:545–553. doi: 10.1038/sj.bjc.6606031. - DOI - PMC - PubMed